Innovhem’s patents protect our BIOMARKERS : An important news !
SINGLE CELL QUANTIFICATION OF FETAL HEMOGLOBIN patent has been issued in France, Nigeria and in the US.
And our 2 patents cover INTRAVASCULAR HEMOLYSIS ASSAY in Europe and in the US.
Stay tuned for future important milestones!
Innovhem proudly shares its latest scientific publication in Haematologica Journal, highlighting our commitment to advancing hematology research. In...
Aventure France 2030 ! 🏆 Hier, à Paris, se tenait le Comité interministériel de l'innovation C2i. Nous sommes fiers de faire partie de...
Another step forward in the fight against sickle cell disease ! On the occasion of the state visit to France by Their Majesties King Frederik X and...
Innovhem to present New data on single-cell quantification of HbF and HbS at the 2024 ASH Annual Meeting. One poster presentation to feature new...
HEMOPROVE is an Open-label One Stage Phase II study sponsored by AP-HP. The investigator hypothesis is that the treatment by Voxelotor (GBT440) will...
INNOVHEM is part of the 4th promotion of SISTA Entrepreneures with AXA FRANCE. This program aims to support the financing of companies run by women.